Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.

ABSTRACT:

Purpose

HER2 overexpression has been associated with a poor prognosis and resistance to therapy in breast cancer patients. We are developing molecular probes for in vivo quantitative imaging of HER2 receptors using near-infrared (NIR) optical imaging. The goal is to provide probes that will minimally interfere with the studied system, that is, whose binding does not interfere with the binding of the therapeutic agents and whose effect on the target cells is minimal.

Experimental design

We used three different types of HER2-specific Affibody molecules [monomer ZHER2:342, dimer (ZHER2:477)2, and albumin-binding domain-fused-(ZHER2:342)2] as targeting agents and labeled them with Alexa Fluor dyes. Trastuzumab was also conjugated, using commercially available kits, as a standard

SUBMITTER: Lee SB 

PROVIDER: S-EPMC3398736 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature